Artivion (NYSE:AORT) Sets New 12-Month High at $21.44

Shares of Artivion, Inc. (NYSE:AORT) reached a new 52-week high during trading on Wednesday . The stock traded as high as $21.44 and last traded at $21.39, with a volume of 66513 shares changing hands. The stock had previously closed at $20.53.

Analysts Set New Price Targets

Several equities analysts have commented on AORT shares. Stifel Nicolaus raised their target price on shares of Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 16th. Needham & Company LLC raised their target price on shares of Artivion from $22.00 to $25.00 and gave the company a “buy” rating in a report on Friday, February 16th.

Artivion Stock Performance

The company has a current ratio of 4.85, a quick ratio of 3.43 and a debt-to-equity ratio of 1.10. The firm’s fifty day moving average is $18.79 and its 200-day moving average is $16.91.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, February 15th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.24. The business had revenue of $93.67 million for the quarter, compared to the consensus estimate of $89.75 million. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. Equities research analysts forecast that Artivion, Inc. will post 0.26 EPS for the current year.

Insider Activity at Artivion

In related news, SVP Marshall S. Stanton sold 2,183 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total transaction of $44,511.37. Following the transaction, the senior vice president now owns 83,296 shares in the company, valued at approximately $1,698,405.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Artivion news, VP Rochelle L. Maney sold 2,315 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.27, for a total transaction of $46,925.05. Following the completion of the sale, the vice president now owns 39,197 shares in the company, valued at approximately $794,523.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Marshall S. Stanton sold 2,183 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total transaction of $44,511.37. Following the sale, the senior vice president now owns 83,296 shares of the company’s stock, valued at approximately $1,698,405.44. The disclosure for this sale can be found here. Insiders have sold 184,743 shares of company stock worth $3,517,865 in the last quarter. Company insiders own 6.60% of the company’s stock.

Institutional Trading of Artivion

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its stake in shares of Artivion by 89.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,677 shares of the company’s stock worth $29,000 after acquiring an additional 791 shares in the last quarter. Captrust Financial Advisors bought a new stake in shares of Artivion in the 2nd quarter worth $39,000. Money Concepts Capital Corp bought a new stake in shares of Artivion in the 4th quarter worth $28,000. Quantbot Technologies LP bought a new stake in shares of Artivion in the 2nd quarter worth $47,000. Finally, State of Wyoming grew its stake in shares of Artivion by 207.1% in the 4th quarter. State of Wyoming now owns 3,495 shares of the company’s stock worth $42,000 after acquiring an additional 2,357 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.